Q-omics provides the consensus-scored NANOS3 profile across patient tissues and cancer cell-line models. NANOS3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NANOS3 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, NANOS3 RNA expression shows 16,192 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, HNSC, and TGCT as cancer lineages where NANOS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOS3 survival associations across molecular data types. NANOS3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOS3 RNA expression–survival associations across cancer types. High NANOS3 expression shows unfavorable associations in ACC and KIRC, but favorable associations in HNSC, KIRP, SCLC and READ. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NANOS3 RNA expression.
This table summarizes NANOS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NANOS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOS3 shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, THCA, UCEC and CHOL. The HNSC box plot shows higher NANOS3 RNA expression in tumor versus normal tissue (log2 FC = +0.578, t-test p < 0.001).
This table shows molecular features associated with NANOS3 in patient tissues and cancer cell lines. In patient samples, NANOS3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NANOS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SKIN.
